Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | S100A9 | P06702 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088403 | 1.00 | ALDH1A1 (0.59) | ALDH1A1NPSR1MAPTLMNAPOLB | |
| SCHEMBL1641646 | 0.82 | ALDH1A1 (0.41) | ALDH1A1NPSR1MAPTLMNAS100A9 | |
| SCHEMBL16139571 | 0.82 | ALDH1A1 (0.41) | ALDH1A1NPSR1MAPTLMNAMAPK1 | |
| SCHEMBL31018073 | 0.81 | ALDH1A1 (0.56) | ALDH1A1NPSR1MAPTLMNAPOLB | |
| SCHEMBL958949 | 0.81 | ALDH1A1 (0.56) | ALDH1A1NPSR1MAPTLMNAPOLB | |
| SCHEMBL7677072 | 0.80 | ALDH1A1 (0.65) | ALDH1A1NPSR1MAPTLMNAPOLB | |
| SCHEMBL2172819 | 0.80 | ALDH1A1 (0.56) | ALDH1A1NPSR1MAPTLMNAL3MBTL1 | |
| SCHEMBL9674592 | 0.80 | S100A9 (0.40) | ALDH1A1NPSR1MAPTLMNAS100A9 | |
| SCHEMBL14934975 | 0.80 | GLP1R (0.43) | ALDH1A1NPSR1MAPTLMNALRRK2 | |
| SCHEMBL10296124 | 0.79 | ALDH1A1 (0.54) | ALDH1A1NPSR1MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011309-A1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | ALLINKY BIOPHARMA (ES) | 2025-01-09 | — | — | US | disclosed |
| US-12071431-B2 | Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta | ALLINKY BIOPHARMA (ES) | 2024-08-27 | — | — | US | disclosed |
| EP-3880668-B1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | ALLINKY BIOPHARMA (ES) | 2023-12-20 | — | — | EP | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4121424-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605467-A | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220002276-A1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | ALLINKY BIOPHARMA (ES) | 2022-01-06 | — | — | US | disclosed |
| WO-2021188944-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3880668-A1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | Allinky Biopharma (ES) | 2021-09-22 | — | — | EP | disclosed |
| CN-113316571-A | Pyridine sulfonamide compounds for treating interleukin-1 beta-related disorders | 阿林齐生物制药公司 | 2021-08-27 | — | — | CN | disclosed |
| WO-2020099603-A1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | ALLINKY BIOPHARMA (ES) | 2020-05-22 | — | — | WO | disclosed |
| US-20140038822-A1 | USE OF SUBSTITUTED SPIROCYCLIC SULFONAMIDOCARBOXYLIC ACIDS, CARBOXYLIC ESTERS THEREOF, CARBOXAMIDES THEREOF AND CARBONITRILES THEREOF OR SALTS THEREOF FOR ENHANCEMENT OF STRESS TOLERANCE IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| WO-2010092342-A1 | ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-6448205-B1 | FOR THE DESICCATION AND/OR DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-10 | — | — | US | disclosed |
| US-6432880-B1 | APPLYING TO PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| CN-1336918-A | Substituted 2-phenylpyridines as herbicides | BASF AG (DE) | 2002-02-20 | — | — | CN | disclosed |
| EP-1140847-A1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042015-A1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011309-A1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | IL1A, IL1B, IL1R1 | ALDH1A1 85/4885NPSR1 951/4885MAPT 3102/4885 |
| US-20220002276-A1 | PYRIDIN-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO INTERLEUKIN 1 BETA | IL1A, IL1B, IL1R1 | ALDH1A1 85/4885NPSR1 951/4885MAPT 3102/4885 |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | HIF1AN, EGLN3, EGLN2 | ALDH1A1 904/4885NPSR1 4535/4885MAPT 4584/4885 |
| US-20140038822-A1 | USE OF SUBSTITUTED SPIROCYCLIC SULFONAMIDOCARBOXYLIC ACIDS, CARBOXYLIC ESTERS THEREOF, CARBOXAMIDES THEREOF AND CARBONITRILES THEREOF OR SALTS THEREOF FOR ENHANCEMENT OF STRESS TOLERANCE IN PLANTS | STS, SCLY, TST | ALDH1A1 1128/4885NPSR1 1683/4885MAPT 4740/4885 |
| US-12071431-B2 | Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta | IL1A, IL1B, IL1R1 | ALDH1A1 85/4885NPSR1 951/4885MAPT 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.